NCT02154022
Collection of Pharmacokinetic Samples From People With Unanticipated Response, Significant Toxicity or Concern of Future Toxicity
Enrolling by Invitation
Not specifiedAges 2+ObservationalNational Cancer Institute (NCI)Government-funded
~100 participants
Updated 2026-07-17 on ClinicalTrials.gov
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To obtain PK sample
Measured over study completion
Conditions
Where it's being run
1 sites across 1 statesMaryland1
Study leadership
- William D Figg, Pharm.D. · PRINCIPAL_INVESTIGATOR · National Cancer Institute (NCI)
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Any individuals greater than or equal to 2 years of age who are currently enrolled in IRB approved NIH Intramural Research Program (IRP) clinical trials are eligible. (Exception: Participants \<18 years old will not be eligible for probe administration.)
Ability of subject or a Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document.
Individuals who have received or are anticipated to receive an investigational agent or FDA approved therapy at the NIH who meet one of the following criteria:
Individuals in whom altered pharmacokinetics are anticipated to occur based on pharmacogenetics, history of toxicities with similar agents, drug interactions, or other patient-specific factors which may alter absorption, distribution, metabolism, or excretion.
What this trial measures
- To obtain PK samplestudy completion
Measure drug concentrations in blood.